Opioid trial begins against Albertsons in Washington state
Washington begins trial against Albertsons for alleged role in opioid epidemic.
Why it matters: The trial could establish corporate accountability standards for pharmacies in opioid distribution. Its outcome may influence future legal and regulatory approaches in the pharmaceutical retail industry.
- Albertsons dispensed over 641 million opioid pills in Washington between 2006-2022.
- More than 6.5 million opioid prescriptions filled by Albertsons showed red flags for misuse.
- In April 2026, Albertsons agreed to a $774 million opioid-related settlement nationwide.
- Washington has secured $1.3 billion from opioid settlements to combat the crisis.
The opioid crisis trial against Albertsons in Washington state officially began in July 2026, marking a significant legal effort to hold pharmacies accountable for their role in the epidemic. Between 2006 and 2022, Albertsons pharmacies dispensed over 641 million opioid pills in Washington alone, operating more than 200 pharmacy locations under the Albertsons, Safeway, and Haggen names.
The state alleges that Albertsons filled more than 6.5 million prescriptions flagged for potential misuse or diversion during this period. These figures underpin the state's argument that Albertsons contributed to the opioid crisis by failing to prevent questionable prescription fulfillment.
Kelsey Endres of the Washington State Attorney General's office emphasized the pharmacy's role as "the last line of defense against potent addictive medication being misused or diverted." The state wants courts to recognize corporate responsibility in monitoring and controlling opioid dispensing practices.
Albertsons defends its practices, with attorney Enu Mainigi stating that "Albertsons always had tools, guidance, and monitoring in place to help pharmacists make safe and appropriate decisions about whether to dispense." Mainigi highlighted that pharmacies operate based on prescriptions written by doctors, alluding to limitations in their control.
In April 2026, Albertsons agreed to a $774 million settlement addressing opioid claims with multiple governments nationwide, including state, local, and tribal entities. Washington state itself has garnered over $1.3 billion from various opioid-related settlements to fund treatment, prevention, and education efforts.
The trial's outcome is anticipated to influence how corporations in the pharmaceutical retail sector manage compliance and liability related to opioid distribution moving forward.
By the numbers:
- 641 million opioid pills — dispensed by Albertsons in Washington (2006-2022)
- 6.5 million prescriptions — filled with red flags for misuse
- $774 million — Albertsons' nationwide opioid settlement in April 2026
- $1.3 billion+ — Washington state opioid settlement funds secured
Yes, but: Albertsons argues their dispensing is contingent on doctors' prescriptions, and they maintain existing safeguards to avoid misuse.